Last reviewed · How we verify
Calquence
At a glance
| Generic name | Calquence |
|---|---|
| Sponsor | iOMEDICO AG |
| Target | Platelet glycoprotein VI, Cytoplasmic tyrosine-protein kinase BMX, Tyrosine-protein kinase Blk |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Chronic lymphocyticleukemia/small lymphocytic lymphoma
- Mantle cell lymphoma
Common side effects
- Upper respiratory tract infection
- Diarrhea
- Headache
- Musculoskeletal pain
- Absolute neutrophil count decreased
- Uric acid increased
- Absolute lymphocyte count decreased
- Platelets decreased
Serious adverse events
- Pneumonia (includes COVID-19 pneumonia)
- COVID-19 (includes COVID-19 pneumonia)
- Second primary malignancy
- Pyrexia
- Rash
- Febrile neutropenia
- Atrial fibrillation
- Sepsis
- Anemia
Key clinical trials
- Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma (PHASE1)
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma (PHASE1, PHASE2)
- Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL (PHASE2)
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calquence CI brief — competitive landscape report
- Calquence updates RSS · CI watch RSS
- iOMEDICO AG portfolio CI